» Articles » PMID: 20225928

TDP-43 and Ubiquitinated Cytoplasmic Aggregates in Sporadic ALS Are Low Frequency and Widely Distributed in the Lower Motor Neuron Columns Independent of Disease Spread

Overview
Publisher Informa Healthcare
Specialty Neurology
Date 2010 Mar 16
PMID 20225928
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Ubiqitinated and TDP-43 immunoreactive cytoplasmic aggregates are hallmark features of ALS molecular pathology. Since clinically most ALS begins focally and advances contiguously, it is important to characterize their distribution. Our objective was to determine the extent and distribution of TDP-43 immunoreactive aggregates in the lower motor neuron columns as a function of disease onset, and to correlate ubiquitinated with TDP-43 aggregates in the lumbar region. We examined TDP-43 cytoplasmic aggregates at four separate neuraxis levels - hypoglossal nucleus and cervical, thoracic, and lumbar anterior horns - in five controls and 20 sporadic ALS nervous systems from patients whose disease began in various sites, i.e. five bulbar, five arm, five trunk, and five leg onsets. We correlated ubiquitinated to TDP-43 aggregates on adjacent histological sections for the lumbar regions. We found that TDP-43 cytoplasmic aggregates are seen in about 8% of motor neurons but there is marked variability between nervous systems, ranging from 0.4% to 20.6%. The aggregates are uniformly distributed within individual nervous systems. There is no obvious correlation between site of disease onset and rate of spread. Almost all ubiquitinated aggregates correlate to TDP-43 aggregates. Thus, TDP-43 immunoreactive cytoplasmic aggregates have a low overall average frequency that does not correlate with either disease course or clinical spread and is the prime ubiquitinated protein.

Citing Articles

CHMP2B promotes CHMP7 mediated nuclear pore complex injury in sporadic ALS.

Keeley O, Mendoza E, Menon D, Coyne A Acta Neuropathol Commun. 2024; 12(1):199.

PMID: 39709457 PMC: 11662732. DOI: 10.1186/s40478-024-01916-7.


Nuclear and degradative functions of the ESCRT-III pathway: implications for neurodegenerative disease.

Keeley O, Coyne A Nucleus. 2024; 15(1):2349085.

PMID: 38700207 PMC: 11073439. DOI: 10.1080/19491034.2024.2349085.


Highly variable molecular signatures of TDP-43 loss of function are associated with nuclear pore complex injury in a population study of sporadic ALS patient iPSNs.

Rothstein J, Warlick C, Coyne A bioRxiv. 2024; .

PMID: 38168312 PMC: 10760028. DOI: 10.1101/2023.12.12.571299.


Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.

Hayes L, Kalab P Neurotherapeutics. 2022; 19(4):1061-1084.

PMID: 35790708 PMC: 9587158. DOI: 10.1007/s13311-022-01260-5.


Emerging Roles for Phase Separation of RNA-Binding Proteins in Cellular Pathology of ALS.

Milicevic K, Rankovic B, Andjus P, Bataveljic D, Milovanovic D Front Cell Dev Biol. 2022; 10:840256.

PMID: 35372329 PMC: 8965147. DOI: 10.3389/fcell.2022.840256.


References
1.
Mori F, Tanji K, Zhang H, Nishihira Y, Tan C, Takahashi H . Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia. Acta Neuropathol. 2008; 116(2):193-203. DOI: 10.1007/s00401-008-0396-9. View

2.
Robertson J, Sanelli T, Xiao S, Yang W, Horne P, Hammond R . Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS. Neurosci Lett. 2007; 420(2):128-32. DOI: 10.1016/j.neulet.2007.03.066. View

3.
Mackenzie I, Bigio E, Ince P, Geser F, Neumann M, Cairns N . Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007; 61(5):427-34. DOI: 10.1002/ana.21147. View

4.
Giordana M, Piccinini M, Grifoni S, de Marco G, Vercellino M, Magistrello M . TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathol. 2009; 20(2):351-60. PMC: 8094784. DOI: 10.1111/j.1750-3639.2009.00284.x. View

5.
Brooks B, Miller R, Swash M, Munsat T . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 1(5):293-9. DOI: 10.1080/146608200300079536. View